Home
overview
 

SMi present their 7th annual conference on Pharmaceutical Portfolio & Product Lifecycle Management. With declining R&D costs, prioritizing a portfolio of successful projects has become essential within the pharmaceutical industry. Lifecycle management approaches must be implemented throughout a products developmental and market period to ensure an increase in profit.  Ultimately, the success of pharmaceutical companies relies on crucial project portfolio decisions and understanding of a product’s lifecycle.


This conference will address the challenges associated with obtaining an optimal portfolio of projects. Senior level industry executives will discuss key strategies and management approaches essential to effective portfolio and lifecycle management.
 

 

Our key speaker line up includes:

Tony Ellery, Managing Director, Ellery Pharma Consulting, Former Global Head LCM in Portfolio Management, Novartis
Kimber Hardy
, Head of Valuation and Analysis, Merck Serono
Tim Harris
, Director, Respiratory & Immuno-inflammation Portfolio Management, GlaxoSmithKline
Christiano Pereira Silva, Global Product Manager for Pradaxa, Boehringer-Ingelheim
Julie Barrett-Major
, Director of Intellectual Property, Norgine
Christine Deuschel, Vice President Portfolio & Project Management, Debiopharm
Anne Lane
, Executive Director, University College London Business
Angel Calvo Yague
, Healthcare Platform Council Member, Gerson Lehman Group Healthcare & Biomedical Council
Boris Kreye
, Lawyer, Bird & Bird
Bruce D Sunstein
, Partner, Sunstein Kann Murphy & Timbers LLP
Kerstin Bode-Greuel
, Lecturer, University of Essen/PME Institute
Graham Cox
, Principal IDEAtor, IDEA Pharma Ltd
Philip Graves
, Market Research Consultant, Philip Graves Consultancy
John Ansell,
 Senior Partner, TranScrip Partners

 

Hear about the current issues involved in optimizing your portfolio


Discuss key strategies employed by pharmaceutical companies in capacity planning and resource allocation


Explore the ways to achieve your portfolios full potential


Learn from real-life case studies presented by senior industry experts


Network with key industry professionals
 



 

 

 

 Heads of Department, Directors, Managers, Team Leaders Researchers and Scientists from:

  • Portfolio Management
  • Lifecycle Management
  • Project Management
  • Portfoio Strategy
  • Strategic Planning
  • Business Development
  • Research & Development
  • Intellectual Property
  • Regulatory Affairs
  • Brand Protection
  • Business Affairs

Previous attendees and participants have come from organisations including:

Actavis UK Ltd
Actelion Pharmaceuticals
Antibiotice S A
AstraZeneca
Baxter
Bayer Healthcare
Biogenerics
Boehringer Ingelheim
Cancer Research UK
Eli Lilly
F. Hoffman La Roche
Galenix
Genentech
GlaxoSmithKline
Leo Pharmaceuticals
Lifescience Dynamics Ltd
Lundbeck A/S
Merck 
Novartis
Novo Nordisk
Nycomed GmbH
Pharmathen SA
Reckitt Benckisser
Sanofi-Aventis
STADA PharmDevelopment Ltd
The Wellcome Trust
Weleda AG
Xplico 

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Tony Ellery

Tony Ellery, Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Ellery Consulting

9:10 Lifecycle management of the portfolio

Tim Harris

Tim Harris, Director, Established Products, EMAP, Global Regulatory Affairs, GlaxoSmithKline

  • Creating the ideas – products and franchises
  • Achieving buy-in – who are the stakeholders and what do they want?
  • Controlling the development – don’t let it run away
  • When to start and when to stop
  • 9:50 Effective Decision Making for R&D Portfolios

  • Outline strategies for managing investment across the development portfolio
  • Discuss how enterprise planning can mitigate increasing operational complexity
  • Show how integrating risk analysis into portfolio planning can help to manage uncertainty
  • Show mechanisms and benefits of integrating real-time clinical trial progress with Portfolio Management
  • Ross Walker

    Ross Walker, Life Sciences Industry Business Unit, Oracle Corporation Uk Limited

    Andrew Davey

    Andrew Davey, Business Development Director, Oracle Corporation Uk Limited

    10:30 Morning Coffee

    11:00 LCM: the view from the frontline

    Jonathan  Gilbert

    Jonathan Gilbert, Senior Brand Director, Astellas Pharma Europe

  • generating real insight and creativity utilising the perspective of the sales rep, physician and the patient.
     
  • 11:40 Assessing portfolio value and risk

    Kimber Hardy

    Kimber Hardy, Head of Valuation and Analysis, Portfolio Management , Merck Serono

  • Technical and commercial uncertainties
  • Project risk assessment
  • Taking a probalistic view: use of Monte Carlo simulation in portfolio value and risk assessment
  • 12:20 Networking Lunch

    13:50 Strategies for pharmaceutical portfolio & product life-cycle management in face of the new U.S. patent law

    Bruce Sunstein

    Bruce Sunstein, Partner, Sustein Kann Murphy & Timbers LLP

  • Why strategies need to be in place right now to address provisions that do not take effect until March 2013
  • How the new US patent law implementing first-inventor-to-file principles is more stringent than European law
  • How the new U.S. grace period provisions reward and punish early publications and later filings
  • How cycles of patent filings over periods of 12, 18, and 30 months can be structured for strategic advantage under the new first-to-file regime
  • 14:30 IP issues in pharma LCM

    Julie Barrett-Major

    Julie Barrett-Major, Director of Intellectual Property, Norgine Ltd

  • Naming (TM and INN) issues
  • Product protection (patents & other) issues
  • Managing conflicting priorities & aims (e.g. publication v. protection)
  • Maximising teamwork & info. sharing
  • 15:10 Afternoon Tea

    15:40 Pharmaceutical Intellectual Property (IP) strategy and practical considerations related to maintenance and enforcement of patents in the EU

    Boris Kreye

    Boris Kreye, Head, Patent Litigation Group, Bird & Bird LLP

  • Selection of Venue
  • Remedies
  • Status of Unitary Patent Protection in the EU
  • Status of Unitary Patent Litigation System
  • 16:20 Portfolio optimization for a generic drug company

  • Generics vs. branded portfolio. What is essential for generics portfolio planning? 
  • Qualitative “filtering” of portfolio candidates
  • Components of portfolio planning system for a generic company
  • Optimal portfolio selection
  • Case studies
  • Angel Calvo Yague

    Angel Calvo Yague, Member, Healthcare & Biomedical Council, Gerson Lehrman Group

    Vladimir Shnaydman

    Vladimir Shnaydman, President, ORBee Consulting

    17:00 Chairman’s Closing Remarks and Close of Day One

    Tony Ellery

    Tony Ellery, Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Ellery Consulting

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Tony Ellery

    Tony Ellery, Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Ellery Consulting

    9:10 LCM – making the most of every brand!

    Tony Ellery

    Tony Ellery, Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Ellery Consulting

  • Patent strategies and market exclusivities
  • Developmental LCM – enhancing the clinical profile
  • Commercial LCM – enhancing patient access
  • Late LCM – competing with generics
  • 9:50 Is There A Fundamental Missing Link In Pharma Development?

    Graham Cox PhD

    Graham Cox PhD, Principal IDEAtor, IDEA Pharma Ltd

  • The 3 Essential Questions Missing From Current R&D
  • What is "Product Design"?
  • Proven Ways to  Improve Your Chances of Success
  • 10:30 Morning Coffee

    11:00 Combination products branch out

    John Ansell

    John Ansell, Senior Partner, TranScrip Partners

  • Today’s Top 10 blockbusters
  • Where fixed combinations are branching out therapeutically
  • Overall trends
  • 11:50 An Enterprise Portfolio and project management (EPPM) Journey – A business critical approach

    Keith Rodgers

    Keith Rodgers, Managing Director, Inspirexe Limited

     

    ·         Selection of a Project and Programme Management system at a biotechnology organisation (a subsidiary of a major pharmaceutical company)
    ·         The strategic process and the impact of M & A.
    ·         Key additional aspects including organisational change, business processes and project management maturity

    12:20 Networking Lunch

    13:20 Collaborations between universities and industry

    Anne Lane

    Anne Lane, Executive Director, UCL Business PLC

    • UCL and UCL Business PLC background
    • University/industry collaborations
      o University environment
      o Government agenda and incentives
      o Industry environment
    • Making the collaboration work
      o Key issues
      o Key personnel
      o Negotiating the agreement
      o Post-agreement management
    • University/industry collaboration case studies

       

    14:00 How to succeed by ignoring your customers (including doctors)

    Philip Graves

    Philip Graves, Managing Director, Philip Graves Consumer Consultancy

  • Market research and the wasted millions
  • Why customers don’t understand
  • The consumer brain
  • Understanding customers better than they do themselves
  • 14:40 Chairman’s Closing Remarks and Close of Day Two

    Tony Ellery

    Tony Ellery, Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Ellery Consulting

    14:50 Afternoon Tea

    +

    The Grange Holborn Hotel

    50-60 Southampton Row
    London WC1B 4AR
    United Kingdom

    The Grange Holborn Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.